The Role of the Pharmaceutical Induestry in Disseminating Pharmacovigilance Practice in Developing Countries

Posted on August 2008 by Segev Shani, Vice President for Medical and Regulatory Affairs in the Neopharm Group and a Lecturer in the Department of Health Systems Management,

63 Food and Drug Law Journal 701-712 (2008). The discipline of pharmacovigilance is based on the reporting of a drug’s adverse events. The regulatory authorities in the developed world, led b...read more

Legal Developments in the Enforcement of Food and Drug Law

Posted on May 2008 by Gerald F. Masoudi, Chief Counsel, Food and Drug Administration, Rockville, MD

63 Food and Drug Law Journal 585-592 (2008). This article contains the prepared text of remarks delivered at the 51st Annual Conference of the Food and Drug Law Institute, March 26, 2008. The paper...read more

Expanded Access to Phase II Clinical Trials in Oncology: A Step Toward Increasing Scientific Validity and Compassion

Posted on May 2008 by Alice K. Marcee, May 2008 J.D. candidate, Dedman School of Law Southern Methodist University, Dallas, TX

63 Food and Drug Law Journal 439-458 (2008). In light of the Supreme Court's recent denial of certiorari in the Abigail Alliance case, FDA and Congress have an opportunity to advance clinical trial...read more

The Foreign Corrupt Practices Act and Clinical Trials: A Trap for the Unwary

Posted on May 2008 by Drew A. Harker, Senior Partner in the Government Contracts and White Collar Criminal Defense Groups, Arnold & Porter LLP, Washington, DC Chad E. Miller,

63 Food and Drug Law Journal 509-524 (2008). The U.S. Foreign Corrupt Practices Act (FCPA) prohibits improper payments by U.S. companies and others to foreign government officials to obtain or reta...read more

Is it Time to Abandon FDA's NO Release from Liability Regulation for Clinical Studies

Posted on May 2008 by John D. Winter, Partner, Paterson Belknap Webb & Tyler LLP, New York, NY

63 Food and Drug Law Journal 525-536 (2008). Federal regulations adopted 30 years ago prohibit sponsors of clinical studies from including waiver of liability provisions in informed consent documen...read more

Federal Trade Commission: Anticipating New Consumer Protection Challenges in the Food and Drug Marketplace

Posted on May 2008 by Lydia B. Parnes, Director of the Bureau of Consumer Protection at the Federal Trade Commission, Washington, DC

63 Food and Drug Law Journal 593-600 (2008). This article contains the prepared text of remarks delivered at the 51st Annual Conference of the Food and Drug Law Institute, March 26, 2008. The paper...read more

The First Amendment and FDA Restrictions on Off-Label Uses: The Call for a New Approach

Posted on May 2008 by Joseph J. Leghorn, Partner in Nixon Peabody, LLP's Product Liability Group, Boston, MA

63 Food and Drug Law Journal 391-406 (2008). Ethical considerations regarding individual health and welfare need not be carelessly disregarded during creation of policies aimed at protecting the&nb...read more

Pharmacy Compounding of BHRT: A New Approach to Justify FDA Regulation of These Prescription Drugs

Posted on May 2008 by Bruce Patsner, Research Professor in the Health Law & Policy Institute at the University of Houston Law Center, Houston, TX

63 Food and Drug Law Journal 459-492 (2008). FDA's recent decision to send warning letters to several pharmacies compounding prescription drugs for "bioidentical" hormone therapy is the latest roun...read more

A Defense of the Learned Intermediary Doctrine

Posted on May 2008 by "Richard B. Goetz, Partner at O'Melveny & Myers LLP, Los Angeles, CA Karen R. Growdon, Counsel at O'Melveny & Myers LLP, Los Angeles, CA"

63 Food and Drug Law Journal 421-438 (2008). The learned intermediary doctrine provides that a prescription drug manufacturer fulfills its duty to warn by providing an adequate warning of the medic...read more

Exploring Emerging Nanobiotechnology Drugs and Medical Devices

Posted on May 2008 by Jordan Paradise, Associate Director of Research and Education of the Joint Degree Program in Law, Health & the Life Sciences, the University of Minnesota Law School in Minneapolis, MN

63 Food and Drug Law Journal 407-420 (2008). "Nanotechnology" expands across research domains, applications and products and remains a field with neither a single scientific definition nor a forma...read more